EMA Authorised: Abrysvo (respiratory syncytial virus vaccine (bivalent, recombinant)) — Pfizer Europe MA EEIG

View source ↗

Summary

EMA has authorised Abrysvo, a bivalent recombinant RSV vaccine, for the prevention of respiratory syncytial virus infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Diseases
• Respiratory Syncytial Virus Infection

Drugs mentioned

• ABRYSVO

Snippet

Status: Authorised. Therapeutic area: Respiratory Syncytial Virus Infections. MAH: Pfizer Europe MA EEIG. Decision date: 25/06/2026. Accelerated assessment